Qu Xiaoli, Wang Qinyi, Luo Chuo, Li Yongfang, Tian Lin, Xu Lulu, Sheng Zhifeng
Health Management Center, National Clinical Research Center for Metabolic Diseases, Hunan Provincial Clinical Medicine Research Center for Intelligent Management of Chronic Disease, Hunan Provincial Key Laboratory of Metabolic Bone Diseases, Department of Metabolism and Endocrinology, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China.
Health Management Center, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China.
BMC Musculoskelet Disord. 2025 May 13;26(1):467. doi: 10.1186/s12891-025-08571-6.
Our study investigated the associations between bone turnover markers (BTMs) and bone mineral density (BMD) and fracture risk over the next 10 years. The objective of the study was to evaluate the potential effects of BTMs in fracture risk.
Our cross-sectional study enrolled 580 participants (380 postmenopausal women and 200 men over the age of 50). All participants completed a questionnaire and dual-energy X-ray absorptiometry examination. We obtained BMD values for the lumbar spine, femoral neck, and total hip joint and biochemical indicators such as creatinine, type 1 procollagen N-terminal propeptide (P1NP), and beta cross-linked C-telopeptide of type 1 collagen (β-CTX). Furthermore, we used an online fracture risk assessment tool (FRAX) to calculate the probability of major osteoporotic fractures (PMOF) and hip fractures (PHF) over the next 10 years. We divided the participants into three groups based on the BMD T-score criteria: normal bone mass group (T-score ≥ - 1.0 SD), osteopenic group (- 2.5 SD < T-score < - 1.0 SD), and osteoporotic group (T-score ≤ - 2.5 SD). We compared differences in BTMs, BMD, and fracture risks among the three groups. Additionally, we evaluated differences in indicators between males and females and explored risk factors associated with BMD and fracture risk.
Postmenopausal women showed higher bone turnover markers, osteoporosis prevalence, and fracture risks compared to men. In a multivariate stepwise regression analysis, we identified P1NP was positively correlated with fracture risk for both PMOF (β = 0.087, p = 0.005) and PHF (β = 0.135, p < 0.001) over the next 10 years. In the logistic regression analysis, after adjusting for sex, we found that for every standard deviation increase in P1NP, the future 10-year risk of fractures increased by approximately 5.2-fold in the high PMOF group and 5.6-fold in the high PHF group.
Our study demonstrated that elevated serum P1NP levels were associated with increased fracture risk over a 10-year period. These findings suggested that serum P1NP measurement could be a valuable complementary tool alongside BMD measurements and FRAX assessments for identifying individuals at high risk of fracture.
我们的研究调查了骨转换标志物(BTMs)与骨密度(BMD)之间的关联以及未来10年的骨折风险。该研究的目的是评估BTMs对骨折风险的潜在影响。
我们的横断面研究纳入了580名参与者(380名绝经后女性和200名50岁以上男性)。所有参与者均完成了问卷调查和双能X线吸收测定检查。我们获取了腰椎、股骨颈和全髋关节的骨密度值以及肌酐、1型前胶原N端前肽(P1NP)和1型胶原β交联C末端肽(β-CTX)等生化指标。此外,我们使用在线骨折风险评估工具(FRAX)计算未来10年发生主要骨质疏松性骨折(PMOF)和髋部骨折(PHF)的概率。我们根据骨密度T值标准将参与者分为三组:骨量正常组(T值≥ -1.0 SD)、骨量减少组(-2.5 SD < T值 < -1.0 SD)和骨质疏松组(T值≤ -2.5 SD)。我们比较了三组之间BTMs、BMD和骨折风险的差异。此外,我们评估了男性和女性之间指标的差异,并探讨了与BMD和骨折风险相关的危险因素。
与男性相比,绝经后女性的骨转换标志物、骨质疏松患病率和骨折风险更高。在多因素逐步回归分析中,我们发现P1NP与未来10年PMOF(β = 0.087,p = 0.005)和PHF(β = 0.135,p < 0.001)的骨折风险均呈正相关。在逻辑回归分析中,在调整性别后,我们发现P1NP每增加一个标准差,高PMOF组未来10年骨折风险增加约5.2倍,高PHF组增加约5.6倍。
我们的研究表明,血清P1NP水平升高与10年内骨折风险增加相关。这些发现表明,血清P1NP检测可能是一种有价值的补充工具,可与骨密度测量和FRAX评估一起用于识别骨折高危个体。